Lilly Research Laboratories, Eli Lilly & Co., Lilly Corporate Center, Indianapolis, Indiana.
Lilly Research Laboratories, Eli Lilly & Co., Lilly Corporate Center, Indianapolis, Indiana
Mol Pharmacol. 2023 Mar;103(3):176-187. doi: 10.1124/molpharm.122.000605. Epub 2022 Dec 12.
An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the dopamine D1 receptor. We synthesized the more active enantiomer of Compound A (BMS-A1) and compared it with the D1 PAMs DETQ and MLS6585, which are known to bind to intracellular loop 2 and the extracellular portion of transmembrane helix 7, respectively. Results from D1/D5 chimeras indicated that PAM activity of BMS-A1 tracked with the presence of D1 sequence in the N-terminal/extracellular region of the D1 receptor, a unique location compared with either of the other PAMs. In pairwise combinations, BMS-A1 potentiated the small allo-agonist activity of each of the other PAMs, while the triple PAM combination (in the absence of dopamine) produced a cAMP response about 64% of the maximum produced by dopamine. Each of the pairwise PAM combinations produced a much larger leftward shift of the dopamine EC than either single PAM alone. All three PAMs in combination produced a 1000-fold leftward shift of the dopamine curve. These results demonstrate the presence of three non-overlapping allosteric sites that cooperatively stabilize the same activated state of the human D1 receptor. SIGNIFICANCE STATEMENT: Deficiencies in dopamine D1 receptor activation are seen in Parkinson disease and other neuropsychiatric disorders. In this study, three positive allosteric modulators of the dopamine D1 receptor were found to bind to distinct and separate sites, interacting synergistically with each other and dopamine, with the triple combination causing a 1000-fold leftward shift of the response to dopamine. These results showcase multiple opportunities to modulate D1 tone and highlight new pharmacological approaches for allosteric modulation of G-protein-coupled receptors.
一个含有胺的分子,被 Bristol-Myers Squibb 的一个团队报道,在多巴胺 D1 受体上作为正变构调节剂(PAM)起作用。我们合成了更具活性的化合物 A 的对映异构体(BMS-A1),并将其与已知分别与细胞内环 2 和跨膜螺旋 7 的细胞外部分结合的 D1 PAMs DETQ 和 MLS6585 进行了比较。D1/D5 嵌合体的结果表明,BMS-A1 的 PAM 活性与 D1 受体的 N 端/细胞外区域中 D1 序列的存在相关,这与其他任何 PAM 都不同。在成对组合中,BMS-A1 增强了其他每个 PAM 的小别构激动剂活性,而三重 PAM 组合(无多巴胺)产生的 cAMP 反应约为多巴胺产生的最大反应的 64%。每个成对 PAM 组合产生的多巴胺 EC 的左移都比单独使用任何一种 PAM 大得多。三种 PAM 联合使用可使多巴胺曲线产生 1000 倍的左移。这些结果表明存在三个非重叠的变构位点,它们协同稳定人类 D1 受体的相同激活状态。 意义陈述:多巴胺 D1 受体的激活不足见于帕金森病和其他神经精神疾病。在这项研究中,发现了三种多巴胺 D1 受体的正变构调节剂,它们结合到不同的、分开的位点,彼此之间以及与多巴胺相互协同作用,三重组合使多巴胺的反应向左移动 1000 倍。这些结果展示了多种调节 D1 音调和突出变构调节 G 蛋白偶联受体的新药理学方法的机会。